Boost for Genomic Health as Oncotype DX makes ASCO (American Society of Clinical Oncology's) guidelines:
This article was originally published in Clinica
Executive Summary
Genomic Health's breast cancer prognostic - Oncotype Dx - has been included in the American Society of Clinical Oncology's (ASCO) updated guidelines. The move could spell a boost in sales for the product, which is used to determine the likelihood of disease recurrence and of chemotherapy benefit for node-negative, oestrogen receptor-positive patients. The guidelines will appear in the Journal of Clinical Oncology on November 20. The inclusion of Oncotype DX is based on multiple independent clinical studies involving over 2,600 patients, claimed the Redwood City, California firm. ASCO guidelines serve as a guide for doctors and outline appropriate methods for treatment and care.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.